FDA announce guidance for Blood Glucose Monitoring Test Systems (BGMS) for Prescription Point-of-Care Use; Guidance for Industry and Food and Drug Administration Staff.
Historically, FDA has not recommended different types of information in 510(k)s for BGMSs used by healthcare professionals as compared to SMBGs intended for home use by lay-users. In order to distinguish between FDA recommendations for prescription-use blood glucose meters, which are intended for use in point-of-care professional healthcare settings, and SMBG devices intended for home